keyword
MENU ▼
Read by QxMD icon Read
search

Fibrotest, FibroSure

keyword
https://www.readbyqxmd.com/read/24964792/the-use-of-transient-elastography-and-fibrotest-for-monitoring-hepatotoxicity-in-patients-receiving-methotrexate-for-psoriasis
#1
Maeve Lynch, Eleanor Higgins, P Aiden McCormick, Brian Kirby, Niamh Nolan, Sarah Rogers, Aoife Lally, Akke Vellinga, Haniza Omar, Paul Collins
IMPORTANCE: There is a need for noninvasive tools to monitor hepatotoxicity in patients with psoriasis who are receiving methotrexate sodium. OBJECTIVE: To evaluate the use of transient elastography (TE) and FibroTest (FibroSURE in the United States), an indirect serum marker of fibrosis, in this population. DESIGN, SETTING, AND PARTICIPANTS: Patients receiving methotrexate therapy for psoriasis between January 2008 and September 2009 were recruited from a dermatology outpatient department...
August 2014: JAMA Dermatology
https://www.readbyqxmd.com/read/24714123/non-invasive-assessment-of-liver-fibrosis
#2
Vasilios Papastergiou, Emmanuel Tsochatzis, Andrew K Burroughs
The presence and degree of hepatic fibrosis is crucial in order to make therapeutic decisions and predict clinical outcomes. Currently, the place of liver biopsy as the standard of reference for assessing liver fibrosis has been challenged by the increasing awareness of a number of drawbacks related to its use (invasiveness, sampling error, inter-/intraobserver variability). In parallel with this, noninvasive assessment of liver fibrosis has experienced explosive growth in recent years and a wide spectrum of noninvasive methods ranging from serum assays to imaging techniques have been developed...
2012: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/24535095/fibrotest-fibrosure-for-significant-liver-fibrosis-and-cirrhosis-in-chronic-hepatitis-b-a-meta-analysis
#3
REVIEW
Nermin N Salkic, Predrag Jovanovic, Goran Hauser, Majda Brcic
OBJECTIVES: Extent of liver fibrosis is one of the most important factors in determining prognosis and the need for active treatment in chronic hepatitis B (CHB). Noninvasive alternatives such as FibroTest/Fibrosure (FT) have been developed in order to overcome the shortcomings of liver biopsy (LB). We aimed to systematically review studies describing the diagnostic accuracy of FT for predicting CHB-related fibrosis. METHODS: MEDLINE and EMBASE searches and hand searching methods were performed to identify studies that assessed the diagnostic accuracy of FibroTest in HB patients using LB as a reference standard...
June 2014: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/21981787/the-impact-of-liver-disease-aetiology-and-the-stages-of-hepatic-fibrosis-on-the-performance-of-non-invasive-fibrosis-biomarkers-an-international-study-of-2411-cases
#4
MULTICENTER STUDY
G Sebastiani, L Castera, P Halfon, S Pol, A Mangia, V Di Marco, M Pirisi, M Voiculescu, M Bourliere, A Alberti
BACKGROUND: Performance of non-invasive fibrosis biomarkers may be influenced by aetiology of chronic liver disease (CLD) and the stages of hepatic fibrosis, but large-scale studies are pending. AIM: To investigate the effect of aetiogy and stages of hepatic fibrosis on the performance of fibrosis biomarkers. METHODS: A total of 2411 patients with compensated CLD (HCV=75.1%, HBV=10.5%, NASH=7.9%, HIV/HCV=6.5%) were consecutively enrolled in 9 centres...
November 2011: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/19519733/systematic-review-non-invasive-methods-of-fibrosis-analysis-in-chronic-hepatitis-c
#5
REVIEW
J O Smith, R K Sterling
BACKGROUND: Accurate determination of the presence and degree of liver fibrosis is essential for prognosis and for planning treatment of patients with chronic hepatitis C virus (HCV). Non-invasive methods of assessing fibrosis have been developed to reduce the need for biopsy. AIM: To perform a review of these non-invasive measures and their ability to replace biopsy for assessing hepatic fibrosis in patients with chronic HCV. METHODS: A systematic review of PUBMED and EMBASE was performed through 2008 using the following search terms: HCV, liver, elastography, hepatitis, Fibroscan, SPECT, noninvasive liver fibrosis, ultrasonography, Doppler, MRI, Fibrotest, Fibrosure, Actitest, APRI, Forns and breath tests, alone or in combination...
September 15, 2009: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/19291784/safe-biopsy-a-validated-method-for-large-scale-staging-of-liver-fibrosis-in-chronic-hepatitis-c
#6
MULTICENTER STUDY
Giada Sebastiani, Philippe Halfon, Laurent Castera, Stanislas Pol, David L Thomas, Alessandra Mangia, Vito Di Marco, Mario Pirisi, Mihai Voiculescu, Maria Guido, Marc Bourliere, Franco Noventa, Alfredo Alberti
UNLABELLED: The staging of liver fibrosis is pivotal for defining the prognosis and indications for therapy in hepatitis C. Although liver biopsy remains the gold standard, several noninvasive methods are under evaluation for clinical use. The aim of this study was to validate the recently described sequential algorithm for fibrosis evaluation (SAFE) biopsy, which detects significant fibrosis (> or =F2 by METAVIR) and cirrhosis (F4) by combining the AST-to-platelet ratio index and Fibrotest-Fibrosure, thereby limiting liver biopsy to cases not adequately classifiable by noninvasive markers...
June 2009: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/17892356/fibromax-towards-a-new-universal-biomarker-of-liver-disease
#7
REVIEW
Rachel Morra, Mona Munteanu, Françoise Imbert-Bismut, Djamila Messous, Vlad Ratziu, Thierry Poynard
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and a better benefit-to-risk ratio than biopsy of five combinations of simple serum biochemical markers (the super combination being FibroMAX (BioPredictive, Paris, France) in patients at risk of chronic liver diseases: FibroTest (BioPredictive) for the quantitative assessment of fibrosis; SteatoTest (BioPredictive) for the quantitative assessment of steatosis; ActiTest (BioPredictive) for the quantitative assessment of necroinflammatory activity in chronic viral hepatitis C and B; NashTest (BioPredictive) for the categorical diagnosis of nonalcoholic steatohepatitis; and AshTest for the quantitative assessment of alcoholic steatohepatitis (also known in the USA as HCV-FibroSURE, HBV-FibroSURE, ASH-FibroSURE and NASH-FibroSURE; LabCorp, NC, USA)...
September 2007: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/16771947/hepatitis-c-in-6-865-patients-65-yr-or-older-a-severe-and-neglected-curable-disease
#8
COMPARATIVE STUDY
Dominique Thabut, Sophie Le Calvez, Vincent Thibault, Julien Massard, Mona Munteanu, Vincent Di Martino, Vlad Ratziu, Thierry Poynard
BACKGROUND: Few data are available on chronic hepatitis C (CHC) in elderly patients. The aim of this study was to compare the features and severity of CHC and the efficacy/safety of antiviral therapy in patients<65, between 65 and 80, and >80 yr old, and to determine the usefulness of biochemical markers (Fibrotest-Fibrosure/ActiTest [FT-AT]) in aged patients. METHODS: This was a retrospective study with two groups of patients: Group 1: prospective cohort including all hepatitis C virus patients from our institution (N=4,182); Group 2: all consecutive patients who had FT-AT performed in France between 2002 and 2004 (N=33,738)...
June 2006: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/16503961/diagnostic-value-of-biochemical-markers-fibrotest-fibrosure-for-the-prediction-of-liver-fibrosis-in-patients-with-non-alcoholic-fatty-liver-disease
#9
MULTICENTER STUDY
Vlad Ratziu, Julien Massard, Frederic Charlotte, Djamila Messous, Françoise Imbert-Bismut, Luninita Bonyhay, Mohamed Tahiri, Mona Munteanu, Dominique Thabut, Jean François Cadranel, Brigitte Le Bail, Victor de Ledinghen, Thierry Poynard
BACKGROUND: Liver biopsy is considered as the gold standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD. METHODS: 170 patients with suspected NAFLD were prospectively included in a reference center (Group 1), 97 in a multicenter study (Group 2) and 954 blood donors as controls...
2006: BMC Gastroenterology
https://www.readbyqxmd.com/read/15723588/fibrotest-fibrosure-towards-a-universal-biomarker-of-liver-fibrosis
#10
Thierry Poynard, Françoise Imbert-Bismut, Mona Munteanu, Vlad Ratziu
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and superior benefit/risk ratio to biopsy of two combinations of simple serum biochemical markers in patients infected with hepatitis B and C virus. These include FibroTest (BioPredictive) for the quantitative assessment of fibrosis, and ActiTest (BioPredictive) for the quantitative assessment of necroinflammatory activity (HCV-FibroSURE, LabCorp). The possible causes of false negatives and positives are also better identified...
January 2005: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/15704051/biomarkers-for-the-prediction-of-liver-fibrosis-in-patients-with-chronic-alcoholic-liver-disease
#11
COMPARATIVE STUDY
Sylvie Naveau, Bruno Raynard, Vlad Ratziu, Annie Abella, Françoise Imbert-Bismut, Djamila Messous, Fabienne Beuzen, Frédérique Capron, Dominique Thabut, Mona Munteanu, Jean Claude Chaput, Thierry Poynard
BACKGROUND & AIMS: The aim of this study was to determine the diagnostic use of noninvasive markers of fibrosis in patients with chronic alcoholic liver disease. METHODS: A total of 221 consecutive patients with an alcohol intake of >50 g/day (median, 100 g/day) and available liver biopsy examination and FibroTest FibroSure (FT) results were included prospectively. Fibrosis was assessed blindly on a 5-stage histologic scale similar to that of the METAVIR scoring system...
February 2005: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/15387887/overview-of-the-diagnostic-value-of-biochemical-markers-of-liver-fibrosis-fibrotest-hcv-fibrosure-and-necrosis-actitest-in-patients-with-chronic-hepatitis-c
#12
Thierry Poynard, Françoise Imbert-Bismut, Mona Munteanu, Djamila Messous, Robert P Myers, Dominique Thabut, Vlad Ratziu, Anne Mercadier, Yves Benhamou, Bernard Hainque
SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and risks of biopsy, as well as the improvement of the diagnostic accuracy of biochemical markers, liver biopsy should no longer be considered mandatory in patients with chronic hepatitis C. In 2001, FibroTest ActiTest (FT-AT), a panel of biochemical markers, was found to have high diagnostic value for fibrosis (FT range 0.00-1.00) and necroinflammatory histological activity (AT range 0.00-1.00). The aim was to summarize the diagnostic value of these tests from the scientific literature; to respond to frequently asked questions by performing original new analyses (including the range of diagnostic values, a comparison with other markers, the impact of genotype and viral load, and the diagnostic value in intermediate levels of injury); and to develop a system of conversion between the biochemical and biopsy estimates of liver injury...
September 23, 2004: Comparative Hepatology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"